Gwendolyn Knowlton Binder-Scholl, Chief Technology Officer at Adaptimmune Therapeutics PLC (ADAP), sold 25,000 shares at $13.79 ($345K) on 2018-10-01, disclosed to the SEC on 2018-10-02.
Open-market sale of $345k ADAP by Chief Technology Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |